CONCLUSIONS: Our results indicate that buprenorphine/naloxone treatment is a promising possibility for patients in need of opiate-substitution treatment.
PMID: 22427466 [PubMed – indexed for MEDLINE] (Source: Neuropsychopharmacologia Hungarica)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
Updated Date: Dec 10, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Updated Date: Dec 10, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
ConclusionsAmong patients with opioid use disorder in Iran, sublingual buprenorphine/naloxone was associated with greater number of opioid‐negative urine tests and treatment retention than oral naltrexone, but not significantly greater initial abstinence duration or proportions with sustained abstinence. This article is protected by copyright. All rights reserved. (Source: Addiction)
ConclusionsAmong patients with opioid use disorder in Iran, sublingual buprenorphine/naloxone was associated with greater number of opioid‐negative urine tests and treatment retention than oral naltrexone, but not significantly greater initial abstinence duration or proportions with sustained abstinence. This article is protected by copyright. All rights reserved. (Source: Addiction)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.